Allogene Therapeutics (ALLO) Competitors $1.27 +0.04 (+3.25%) Closing price 04:00 PM EasternExtended Trading$1.28 +0.01 (+1.18%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLO vs. ELVN, PRAX, IMTX, WVE, DNTH, ORIC, PHAR, COLL, IMNM, and RAPPShould you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include Enliven Therapeutics (ELVN), Praxis Precision Medicines (PRAX), Immatics (IMTX), WAVE Life Sciences (WVE), Dianthus Therapeutics (DNTH), Oric Pharmaceuticals (ORIC), Pharming Group (PHAR), Collegium Pharmaceutical (COLL), Immunome (IMNM), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry. Allogene Therapeutics vs. Its Competitors Enliven Therapeutics Praxis Precision Medicines Immatics WAVE Life Sciences Dianthus Therapeutics Oric Pharmaceuticals Pharming Group Collegium Pharmaceutical Immunome Rapport Therapeutics Allogene Therapeutics (NASDAQ:ALLO) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings. Is ALLO or ELVN more profitable? Enliven Therapeutics' return on equity of -29.15% beat Allogene Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allogene TherapeuticsN/A -55.99% -42.75% Enliven Therapeutics N/A -29.15%-27.88% Does the media favor ALLO or ELVN? In the previous week, Allogene Therapeutics and Allogene Therapeutics both had 6 articles in the media. Enliven Therapeutics' average media sentiment score of 0.39 beat Allogene Therapeutics' score of 0.23 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Enliven Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ALLO or ELVN? Allogene Therapeutics currently has a consensus price target of $8.44, indicating a potential upside of 564.92%. Enliven Therapeutics has a consensus price target of $41.20, indicating a potential upside of 89.60%. Given Allogene Therapeutics' higher possible upside, equities research analysts clearly believe Allogene Therapeutics is more favorable than Enliven Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allogene Therapeutics 2 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.54Enliven Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has better valuation & earnings, ALLO or ELVN? Enliven Therapeutics has lower revenue, but higher earnings than Allogene Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllogene Therapeutics$20K14,089.38-$257.59M-$1.11-1.14Enliven TherapeuticsN/AN/A-$89.02M-$2.00-10.87 Which has more volatility & risk, ALLO or ELVN? Allogene Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Do institutionals & insiders have more ownership in ALLO or ELVN? 83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 25.9% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryEnliven Therapeutics beats Allogene Therapeutics on 8 of the 13 factors compared between the two stocks. Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLO vs. The Competition Export to ExcelMetricAllogene TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$272.91M$3.38B$6.11B$10.47BDividend YieldN/A2.29%5.73%4.77%P/E Ratio-1.1422.7785.3627.36Price / Sales14,089.38483.07607.44135.43Price / CashN/A46.7037.4661.86Price / Book0.6310.5512.426.81Net Income-$257.59M-$52.58M$3.32B$276.80M7 Day Performance-13.61%1.09%1.01%0.27%1 Month Performance10.43%16.09%10.75%8.31%1 Year Performance-53.14%18.41%76.20%35.60% Allogene Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLOAllogene Therapeutics2.5795 of 5 stars$1.27+3.3%$8.44+564.9%-53.2%$272.91M$20K-1.14310Analyst DowngradeELVNEnliven Therapeutics2.562 of 5 stars$20.30+3.5%$41.20+103.0%-27.6%$1.16BN/A-10.1550PRAXPraxis Precision Medicines2.0255 of 5 stars$50.98-6.3%$85.56+67.8%-25.0%$1.14B$8.55M-4.15110IMTXImmatics2.6948 of 5 stars$9.39-0.1%$15.00+59.7%+9.4%$1.14B$168.65M-14.45260News CoverageAnalyst UpgradeAnalyst RevisionWVEWAVE Life Sciences4.5248 of 5 stars$7.22+1.0%$20.33+181.6%-9.6%$1.14B$93.95M-8.02240News CoverageGap UpDNTHDianthus Therapeutics3.1493 of 5 stars$34.46-1.4%$61.57+78.7%+39.8%$1.12B$6.24M-10.6080News CoverageAnalyst ForecastORICOric Pharmaceuticals4.2656 of 5 stars$14.41+24.7%$17.29+20.0%+37.9%$1.12BN/A-7.6280Gap UpHigh Trading VolumePHARPharming Group2.1233 of 5 stars$15.38-4.7%$30.00+95.1%+71.0%$1.11B$297.20M-118.31280COLLCollegium Pharmaceutical4.0519 of 5 stars$33.83-2.3%$42.33+25.1%-15.3%$1.09B$631.45M32.53210IMNMImmunome1.7351 of 5 stars$14.41+16.4%$23.20+61.0%+16.0%$1.08B$9.04M-4.6840RAPPRapport Therapeutics2.7967 of 5 stars$27.74-2.8%$35.33+27.4%+2.0%$1.04BN/A-11.10N/A Related Companies and Tools Related Companies ELVN Competitors PRAX Competitors IMTX Competitors WVE Competitors DNTH Competitors ORIC Competitors PHAR Competitors COLL Competitors IMNM Competitors RAPP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLO) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
